<DOC>
	<DOCNO>NCT01925027</DOCNO>
	<brief_summary>Our hypothesis test 1 ) The safety efficacy Nano+ DES patient de novo lesion ; 2 ) A low neointimal hyperplasia Nano+ DES implantation due effective sufficient antiproliferative drug ; 3 ) A high coverage improve early arterial heal Nano+ DES implantation due polymer-free ; 4 ) The safety clopidogrel treatment discontinuation 3 month OCT result define optimal .</brief_summary>
	<brief_title>Efficacy Safety Nano+ Polymer-free Sirolimus-Eluting Stent : A Optical Coherent Tomography Study</brief_title>
	<detailed_description>Eligibility criterion : - 18 85 year . - Evidence myocardial ischemia without raise troponin ( e.g . stable unstable angina , silent ischemia demonstrate positive territorial functional study ) . - The patient plan intervention two de novo lesion different epicardial vessel - Lesion ( ) must visually estimate diameter stenosis ≥50 % &lt; 100 % . - Lesion length must &lt; 18mm - RVD must 2.5-4.0 mm - Written inform consent . - The patient patient 's physician agree follow-up visit include angiographic follow-up OCT assessment 3 month . Design detail outcomes This prospective , multicentre , single arm , open- label study , enroll total 45 patient 5 European investigational site . All patient treat Nano+ Polymer-free Sirolimus Coronary Stent System . All patient undergo angiographic ( QCA ) investigation baseline ( pre- post-procedure ) 3 month follow-up . All patient undergo OCT investigation 3 month follow-up . OCT investigation perform 6 month follow-up patient OCT criterion ( coverage stent apposition ) meet 3 month OCT. Off-line OCT angiographic data analysis undertaken independent core laboratory ( Cardialysis BV , Rotterdam , The Netherlands ) blind clinical procedural characteristic patient accord pre-set Standard Operating Procedures . All patient evaluate clinically 3 , 4 , 5 month ( patient 6 month OCT follow-up evaluation 8 month ) 1 2 year . Clinical data adjudicate independent Clinical Event Committee . An independent Data Safety Monitoring Board ( DSMB ) monitor individual collective safety patient study ongoing basis . This hypothesis generate study , evidence expect magnitude effect available present . Data generate study compare ( historical control ) historical figure drug elute stent available Cardialysis , publish data .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>18 85 year . Evidence myocardial ischemia without raise troponin ( e.g . stable unstable angina , silent ischemia demonstrate positive territorial functional study ) . The patient plan intervention two de novo lesion different epicardial vessel Lesion ( ) must visually estimate diameter stenosis ≥50 % &lt; 100 % . Lesion length must &lt; 18mm RVD must 2.54.0 mm Written inform consent . The patient patient 's physician agree followup visit include angiographic followup OCT assessment 3 month . Evidence ongoing acute myocardial infarction ECG prior procedure . LVEF &lt; 30 % . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) . Known renal insufficiency ( e.g. , eGFR &lt; 60 ml/kg/m2 serum creatinine level &gt; 2.5 mg/dL , subject dialysis ) . History bleed diathesis coagulopathy . The patient recipient heart transplant . Known hypersensitivity contraindication aspirin , heparin bivalirudin , antiplatelet medication specify use study ( clopidogrel prasugrel , ticagrelor ticlopidine ) , sirolimus stainless steel . Other medical illness ( e.g . cancer , stroke neurological deficiency ) know history substance abuse ( alcohol , cocaine , heroin etc . ) per physician judgment may cause noncompliance protocol confound data interpretation associate limited life expectancy Participating drug medical device clinical trial , prior reach primary endpoint . Pregnant breastfeed woman woman fertile period take adequate contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Nano+ DES</keyword>
	<keyword>OCT</keyword>
	<keyword>Neointimal hyperplasia</keyword>
	<keyword>DAPT</keyword>
	<keyword>3 month</keyword>
</DOC>